ClinicalTrialsFinder
RecruitingPhase 1Phase 2NCT07178431

MB-CART2019.1 in Refractory Multiple Sclerosis

An Open Label Phase I/IIa, Multicenter, Interventional Single-arm Trial of MB-CART 2019.1 in Patients With Refractory Multiple Sclerosis (MS)

Sponsor

Miltenyi Biomedicine GmbH

Enrollment

26 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

Multiple SclerosisCAR-T Cell Therapy

Summary

The goal of this trial is to assess the feasibility, safety and preliminary efficacy of MB-CART2019.1 in patients with active refractory primary and secondary progressive MS.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called MB-CART2019.1 for people with car-t cell therapy and multiple sclerosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALMB-CART2019.1

CAR T cell therapy

Locations(1)

Charité Universitätsmedizin Berlin

Berlin, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07178431

Related Trials

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT0622020135 locations

Single Arm Trial Identifying Barriers and Facilitators to Mindfulness Practice

NCT075732411 location

Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)

NCT077207651 location

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients

NCT070855071 location

A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

NCT064337651 location